Showing 2371-2380 of 2807 results for "".
- Study: Lumenato Boosts Skin Barrier Function, Collagen and Ceramideshttps://modernaesthetics.com/news/study-lumenato-boosts-skin-barrier-function-collagen-and-ceramides/2473526/Lycored's Lumenato may improve the skin barrier function and boost collagen and ceramides after 12 weeks of daily supple
- New York City Plastic Surgeon Dr. Scot Bradley Glasberg Named New Plastic Surgery Foundation Presidenthttps://modernaesthetics.com/news/new-york-city-plastic-surgeon-dr-scot-bradley-glasberg-named-new-plastic-surgery-foundation-president/2473525/Scot Bradley Glasberg, MD, FACS, is the new president of The Plastic Surgery Foundation (The PSF), which supports research and international efforts of the American Society of Plastic Surgeons (ASPS). He began his one-year term at the Plastic Surgery: The Meeting in Austin, Texas.
- Revance Taps Erica Jordan as CCOhttps://modernaesthetics.com/news/revance-taps-erica-jordan-as-coo/2473522/Erica Jordan is now Revance Therapeutics, Inc.’s Chief Commercial Officer (CCO), Aesthetics. “Given the importance of the DAXXIFY launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having wo
- Study Highlights Benefits of Nonsurgical Rhinoplasty With PDO Max Threadshttps://modernaesthetics.com/news/study-highlights-benefits-of-nonsurgical-rhinoplasty-with-pdo-max-threads/2473521/Non-surgical rhinoplasty using polydioxanone (PDO) threads can safely achieve minor nasal changes especially in tip rotation and appearance of dorsal hump, according to research in the Journal of Cosmetic Dermatology. The pr
- Natrelle Unveils New "For Every BODY" Campaignhttps://modernaesthetics.com/news/natrelle-unveils-new-for-every-body-campaign/2473519/Allergan Aesthetics’ is launching "For Every BODY," a new Natrelle campaign that showcases how the Natrelle breast implant portfolio can provide a customized look for every body. "Our mar
- Meet Sylke, the First Wound Dressing Made of Pure Hypoallergenic Silk Fibroinhttps://modernaesthetics.com/news/meet-sylke-the-first-wound-dressing-made-of-pure-hypoallergenic-silk-fibroin/2473511/Sylke Inc. is launching SYLKE, the first dressing made of pure hypoallergenic silk fibroin. SYLKE is designed to enhance healing across surgical wounds and to reduce complications and infections which can lead to poor scarring outcomes. In a study published in the
- Revision Skincare Unveils New "The Science Is Black and White" Brand Campaignhttps://modernaesthetics.com/news/revision-skincare-unveils-new-the-science-is-black-and-white-brand-campaign/2473507/Revision Skincare is rolling out its new brand campaign: "The Science Is Black and White." The campaign, which emphasizes that there are no gray areas when it comes to results, speaks to both consumers and skincare providers. Revision Skincare will be cel
- Hair Relaxers Linked to Uterine Cancer in Black Womenhttps://modernaesthetics.com/news/hair-relaxers-linked-to-uterine-cancer-in-black-women/2473506/Long-term use of chemical hair relaxers by postmenopausal Black women may increase risk of uterine cancer, according to a new study by researchers at Boston University’s Black Women’s Health Study (BWHS). These products contain potentially harmful ingredients, including chem
- BeautyHealth Launches New Hydrafacial School Partner Program for Student Estheticianshttps://modernaesthetics.com/news/beautyhealth-launches-new-hydrafacial-school-partner-program-for-student-estheticians/2473505/The Beauty Health Company is introducing the Hydrafacial School Partner Program to accredited esthetic schools across the U.S. Piloted first with select Paul Mitchell Schools and Aveda Institute locations, the Hydrafacial School Partner Program offers participating schools and the
- RelabotulinumtoxinA Update from Galdermahttps://modernaesthetics.com/news/relabotulinumtoxina-update-from-galderma/2473504/The U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) to Galderma related to its pending Biologics License Application (BLA) for RelabotulinumtoxinA for the treatment of moderate-to-severe glabellar lines associated with corrugator and/or procerus muscle activity